FDA cleared Baxfendy (baxdrostat) Monday, and AstraZeneca is already calling peak sales above $5 billion. The drug is the first aldosterone synthase inhibitor approved for hypertension in the U.S.
Leerink Partners is more bullish, pegging potential at up to $10 billion if the drug succeeds in additional indications. Worldwide, some 1.4 billion people have hypertension; AstraZeneca puts the U.S. treatable market at around 23 million patients.
Baxfendy is indicated for uncontrolled or treatment-resistant hypertension, used alongside other antihypertensives. It blocks the aldosterone synthase enzyme, which induces sodium retention and drives blood pressure higher. Phase 3 BaxHTN trial data, published in the New England Journal of Medicine in August 2025, showed the 2-mg dose lowering systolic blood pressure by 9.8 mmHg versus placebo at 15 weeks. Even the 1-mg dose delivered 8.7 mmHg of improvement.
AstraZeneca didn’t build this one in-house. The pharma bought CinCor Pharma in 2023 for $1.3 billion to get baxdrostat. With Baxfendy now cleared and $5 billion in peak sales on the horizon, that acquisition looks like a bargain. The drug is tagged as a key launch toward AstraZeneca’s $80 billion revenue goal by 2030, with late-stage programs running in primary aldosteronism, chronic kidney disease, and heart failure prevention.
One competitor won’t be far behind. Mineralys Therapeutics’ lorundrostat, another aldosterone synthase inhibitor, had its NDA accepted by FDA in March. A decision is due in December.
Sarah Chen